Schnitzler Syndrome
📧 Sign up to get email alerts when something new happens for Schnitzler Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: AutoInflammatory Disease Alliance Registry (AIDA)
The AutoInflammatory Disease Alliance Registry (AIDA) is currently recruiting to collect data on hereditary autoinflammatory diseases. The c…
-
CLINICAL_TRIALS withdrawal · 2024-11-15Clinical Trial Update: Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome [Phase 2]
A Phase 2 clinical trial evaluating the efficacy and safety of RPH-104 for Schnitzler syndrome (including associated urticarial vasculitis w…
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: Tocilizumab in Patients With Schnitzler's Syndrome [Phase 2]
Phase 2 clinical trial evaluating tocilizumab in Schnitzler's Syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Ilaris (Canakinumab) in the Schnitzler Syndrome [Phase 2]
Phase 2 trial of canakinumab (Ilaris) in Schnitzler Syndrome has been completed.
-
CLINICAL_TRIALS trial_result · 2018-07-17Clinical Trial Update: Ilaris® Effects in Schnitzler Syndrome (ILESCH) [Phase 2]
A Phase 2 trial evaluating canakinumab (Ilaris) for Schnitzler syndrome has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-05-31Clinical Trial Update: Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) [Phase 2]
Phase 2 clinical trial assessing the safety and tolerability of rilonacept in patients with Muckle-Wells Syndrome and Schnitzler Syndrome; t…
-
CLINICAL_TRIALS trial_result · 2012-05-24Clinical Trial Update: Efficacy and Safety of Canakinumab in Schnitzler Syndrome [Phase 2]
Phase 2 trial evaluating the efficacy and safety of canakinumab in Schnitzler syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2007-03-01Clinical Trial Update: The Efficacy and Safety of ITF2357 in AIS [Phase 2]
Phase 2 clinical trial update evaluating ITF2357 (givinostat) for autoinflammatory syndromes, including Hyper-IgD syndrome, TNF receptor-ass…